Biosense Webster Varipulse PFA system performs well with minimal adverse events

The late-breaking U.S. multicenter admIRE clinical trial at the Heart Rhythm Society 2024 meeting, showed positive data on the long-term safety and effectiveness of the the Biosense Webster Varipulse pulsed field ablation (PFA) system in patients with paroxysmal atrial fibrillation. #HRS #HRS2024 #PFA

The admIRE clinical trial results presented at the Heart Rhythm Society 2024 meeting showed positive data on the long-term safety and effectiveness of the the Biosense Webster Varipulse pulsed field ablation (PFA) system.

"This was the first PFA IDE study to support a substantial number of fluoro-free procedures," said presenter Vivek Reddy, MD.